全國(guó)服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡(jiǎn)要描述：Acamprosate calcium 77337-73-6Acamprosate, also known by the brand name Campral?, is a drug used for treating alcohol dependence.
產(chǎn)品型號(hào)：abs47027813廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2025-12-31訪 問 量：739產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 77337-73-6 |
|---|---|---|---|
| 分子式 | C10H20CaN2O8S2 | 純度 | ＞98% |
| 分子量 | 400.48 | 貨號(hào) | abs47027813 |
| 規(guī)格 | 25mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used for treating alcohol dependence. | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Acamprosate calcium 77337-73-6
| 產(chǎn)品描述 | |
| 描述 | Acamprosate, also known by the brand name Campral?, is a drug used for treating alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug. |
| 純度 | ＞98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 阿坎酸鈣；Calcium N-acetylhomotaurinate |
| 外觀 | powder |
| 可溶性/溶解性 | water : 20.2 mg/mL (100 mM) |
| 生物活性 | |
| 靶點(diǎn) | GABA Receptor |
| In vitro(體外研究) | Acamprosate binds to a specific spermidine-sensitive site that modulates the NMDA receptor in a complex way. |
| In vivo(體內(nèi)研究) | Acamprosate is absorbed via the gastrointestinal tract, with pharmacokinetic linearity in terms of dose and time. Absolute bioavailability of acamprosate under fasting conditions is approximately 11%. After food intake, bioavailability decreases by approximately 20%, but this decrease lacks clinical significance. Steady-state plasma concentrations of acamprosate are reached within 5 days of dosing and the terminal half-life ranges from 20–33 hours following the standard 2 × 333 dosing regime. Plasma protein binding is negligible. Acamprosate is not metabolized in the liver and is excreted unchanged in the urine. Acamprosate may have neuroprotective effects. Acamprosate appears to work by normalizing the dysregulation of NMDA-mediated glutamatergic neurotransmission that occurs during chronic alcohol consumption and withdrawal, and thus attenuates one of the physiological mechanisms that may prompt relapse. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：